PPL 100

Drug Profile

PPL 100

Alternative Names: MK-8122; PL-100; PPL-100; TMB-607

Latest Information Update: 20 May 2016

Price : $50

At a glance

  • Originator Ambrilia Biopharma
  • Developer Ambrilia Biopharma; TaiMed Biologics
  • Class Aniline compounds; Antiretrovirals; Benzhydryl compounds; Carbamates; Phosphoric acid esters; Small molecules; Sulfonamides
  • Mechanism of Action HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical HIV infections

Most Recent Events

  • 20 May 2016 PPl 100 (SC, IM) is still in preclinical development for HIV infections in Taiwan
  • 09 Jul 2013 No development reported - Phase-I for HIV infections in Canada (PO)
  • 11 Dec 2007 MK 8122 is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top